View Archive

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck & Co., Inc., and TESARO.

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

ASCO: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy, and Beyond!

ASCO: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy, and Beyond!

Saturday, June 1, 2019

Dinner and Registration: 6:30 PM – 7:00 PM
Program:7:00 PM - 9:00 PM

Hyatt Regency Chicago
Regency Ballroom C-D (Gold Level, West Tower)
151 E. Wacker Drive
Chicago, IL 60601


The landscape of therapeutic options for patients with ovarian cancer continues to evolve at a rapid pace. Multiple poly(ADP-ribose) polymerase (PARP) inhibitors have been approved for both treatment and ongoing maintenance indications following the results of recent key studies. These approvals have heralded an opportunity to significantly improve outcomes for patients with ovarian cancer. Other trials in ovarian cancer are exploring the use of a variety of different agents, both as monotherapy and in combination. The accelerated pace and volume of clinical advancements associated with the treatment of ovarian cancer present a challenge for you to stay current and arm yourself with the clinical knowledge and insight necessary to optimize safety and efficacy outcomes.

To help you meet this challenge, this symposium will feature a panel of experts in the management of ovarian cancer who will present and assess the latest data on PARP inhibition and several other classes of therapy that are being explored in the field. The faculty will discuss clinical implications of the data for contemporary practice in a case-based format. During this case-based activity, clinical scenarios will be presented that explore nuances of patient care along the disease continuum. Consideration and attention to best practices for selection of treatment and maintenance approaches in multiple lines of therapy will be broached, as well as strategies for mitigation of predictable treatment-associated adverse events. Future directions in the treatment of ovarian cancer will also be addressed.

Benefits of Attending

  • Gain the insights of leading clinical experts on data for established and emerging treatment options in the management of ovarian cancer
  • Develop strategies to optimize treatment selection for your patients with ovarian cancer
  • Enhance approaches to the mitigation and management of treatment-associated adverse events for patients with ovarian cancer
  • Network with your colleagues and clinical experts in the management of ovarian cancer

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck & Co., Inc., and TESARO.

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Target Audience

This educational program is directed toward the ASCO Annual Meeting audience, including medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists. Other attendees of the ASCO Annual Meeting who have an interest in the treatment of ovarian cancer, such as obstetrician/gynecologists, nurses, physician assistants, fellows, and residents, are also invited to participate.

Educational Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Summarize key safety and efficacy outcomes from clinical trials that have evaluated PARP inhibitors for ovarian cancer management
  • Examine evidence related to the timing and selection of molecular testing methods for patients with ovarian cancer
  • Outline recent data on emerging approaches for the management of patients with ovarian cancer
  • Identify practical strategies to manage adverse events encountered with the use of emerging therapeutic options for patients with ovarian cancer

Program Chair

Robert L. Coleman, MD, FACOG, FACS
Professor and Executive Director, Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Click to see all our ASCO programs!


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

Please note that attendance is on a first-come, first-served basis. Please arrive early to ensure your spot!

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.    

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Calendar of Events
Filter By